The Effect of Metformin on Obesity and Metabolic Disturbance in Patients Taking Clozapine

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.

The purpose of this study is the evaluation of effect of metformin on obesity and metabolic disturbance in patients taking clozapine.

Condition or disease

Intervention/treatment

Phase

Schizophrenia

Drug: MetforminDrug: Placebo (for metformin)

Phase 4

Detailed Description:

In this study, the investigators are going to examine the effect of metformin on obesity and metabolic disturbance in patients with schizophrenia who have taken clozapine.The metformin 500mg will be administrated per oral twice a day for 24 weeks and for control group, placebo will be given same route and process.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:

18 Years to 65 Years (Adult)

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

No

Criteria

Inclusion Criteria:

Age: 18 ~ 65

Patient with schizophrenia according to DSM-IV criteria

Patient have signed on the informed consent, and well understood the objective and procedure of this study.

Patient taking clozapine 3months or more

Patient increased in weight more than 10 % of that of before antipsychotics use